Clinical Trial

Edesa Biotech Reports Fiscal Year 2024 Results

TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics…

2 weeks ago

Outlook Therapeutics® Streamlines Operations

Full NORSE EIGHT Data Readout Expected January 2025ISELIN, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK),…

2 weeks ago

Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Carlsbad, CA, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage…

2 weeks ago

Medical Writing Market Size Indicating $ 9.09 billion by 2031, Featuring Profiles of Cactus Communications, Certara, Covance, Freyr Solutions, InClin Inc

The report from The Insight Partners lists several stakeholders—including pharmaceutical and biotech companies, CROs, regulatory authorities, healthcare providers, and academic…

2 weeks ago

Positioned for growth, patient recruitment company 1nHealth appoints Kayt Leonard as its first chief commercial officer

ORLANDO, Fla., Dec. 13, 2024 /PRNewswire/ -- 1nHealth, a digital patient recruitment company accelerating enrollment for clinical trials, announces the appointment…

2 weeks ago

IAVI and IPD Sign Agreement Formalizing Collaboration to Advance Vaccine Development, Manufacturing, and Access in Africa

Agreement signed to establish collaboration between IAVI and IPDNew partnership aims to accelerate vaccine development and manufacturing for priority pathogens…

2 weeks ago

Ainos Joins Webull Corporate Connect Service Platform to Enhance Investor Engagement

SAN DIEGO, CA / ACCESSWIRE / December 13, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare…

2 weeks ago

Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Single-agent MDNA11 was more effective than a combination of immune checkpoint inhibitors (anti-mPD1 and anti-mCTLA4) in preventing metastasis and achieving…

2 weeks ago

Angle PLC Announces HER2 Presentation at SABCS

WEILL CORNELL MEDICINE PRESENTS HER2 PARSORTIX WORKFLOW AT SAN ANTONIO BREAST CANCER SYMPOSIUMIndependent findings support ANGLE's HER2 assay development programmePotential…

2 weeks ago